Randomized Study to Compare the Bioavailability of Three Mometasone Furoate 0.1% Topical Lotions

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Perrigo Company
ClinicalTrials.gov Identifier:
NCT00805155
First received: December 5, 2008
Last updated: March 15, 2012
Last verified: March 2012
  Purpose

The purpose of this study was to compare the relative vasoconstrictive effects of two test and one reference Mometasone Furoate 0.1% Topical Lotions in healthy, female subjects.


Condition Intervention
Healthy
Drug: Mometasone Furoate 0.1% Topical Lotion-Reference Product
Drug: Mometasone Furoate 0.1% Topical Lotion-Test product 1
Drug: Mometasone Furoate 0.1% Topical Lotion-Test Product 2

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Bioequivalence of Three Mometasone Furoate 0.1% Topical Lotions

Resource links provided by NLM:


Further study details as provided by Perrigo Company:

Primary Outcome Measures:
  • Vasoconstriction will be measured by the degree of skin blanching observed after treatment removal using a ChromaMeter [ Time Frame: Over the course of two days ] [ Designated as safety issue: No ]

Enrollment: 80
Study Start Date: February 2004
Study Completion Date: March 2004
Primary Completion Date: March 2004 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Cohort Group 1
Subjects number 1 to 20
Drug: Mometasone Furoate 0.1% Topical Lotion-Reference Product
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Drug: Mometasone Furoate 0.1% Topical Lotion-Test product 1
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Drug: Mometasone Furoate 0.1% Topical Lotion-Test Product 2
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Cohort Group 2
Subjects number 21 to 50
Drug: Mometasone Furoate 0.1% Topical Lotion-Reference Product
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Drug: Mometasone Furoate 0.1% Topical Lotion-Test product 1
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Drug: Mometasone Furoate 0.1% Topical Lotion-Test Product 2
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Cohort Group 3
Subject Numbers 51 to 80
Drug: Mometasone Furoate 0.1% Topical Lotion-Reference Product
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Drug: Mometasone Furoate 0.1% Topical Lotion-Test product 1
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
Drug: Mometasone Furoate 0.1% Topical Lotion-Test Product 2
Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Healthy Community Volunteers

Criteria

Inclusion Criteria:

  • Non-tobacco using female subjects, 18 to 50 years of age
  • Demonstrated blanching response to Reference Drug
  • Body Mass Index (BMI) of 30 or less
  • Good health as determined by lack of clinically significant abnormalities in medical history and clinical assessment, as judged by the Investigator
  • Signed and dated informed consent form which meets all criteria of current FDA regulations

Exclusion Criteria:

  • History of allergy to systemic or topical corticosteroids
  • Presence of any skin condition or coloration that would interfere with the placement of test sites or the response or assessment of skin blanching
  • Presence of medical condition requiring regular treatment with prescription drugs
  • Drug or alcohol addiction requiring treatment in the past 12 months prior to dosing
  • Use of any tobacco products in the 30 days prior to study dosing
  • Use of any dermatological drug therapy on the flexor surface of the forearms within 30 days of dosing
  • Receipt of any drugs as part of a research study within 30 days prior to study dosing
  • Pregnant or lactating
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Perrigo Company
ClinicalTrials.gov Identifier: NCT00805155     History of Changes
Other Study ID Numbers: 10316908
Study First Received: December 5, 2008
Last Updated: March 15, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Perrigo Company:
Bioequivalence
Mometasone Furoate

Additional relevant MeSH terms:
Mometasone furoate
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Allergic Agents

ClinicalTrials.gov processed this record on September 18, 2014